Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial (vol 7, e214761, 2021)

被引：0
|
作者：
Feng, Jean [1 ]
Friesner, Isabel [1 ]
Hong, Julian C. [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA USA
来源：
JAMA ONCOLOGY | 2024年 / 10卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1443 / 1443
页数：1
相关论文
共 50 条
  • [31] Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
    Planchard, David
    Kim, Tae Min
    Mazieres, Julien
    Quoix, Elisabeth
    Riely, Gregory
    Barlesi, Fabrice
    Souquet, Pierre-Jean
    Smit, Egbert F.
    Groen, Harry J. M.
    Kelly, Ronan J.
    Cho, B. C.
    Socinski, Mark A.
    Pandite, Lini
    Nase, Christine
    Ma, Bo
    D'Amelio, Anthony, Jr.
    Mookerjee, Bijoyesh
    Curtis, C. Martin, Jr.
    Johnson, Bruce E.
    LANCET ONCOLOGY, 2016, 17 (05): : 642 - 650
  • [32] Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial
    Mazieres, Julien
    Paik, Paul K.
    Garassino, Marina C.
    Le, Xiuning
    Sakai, Hiroshi
    Veillon, Remi
    Smit, Egbert F.
    Cortot, Alexis B.
    Raskin, Jo
    Viteri, Santiago
    Wu, Yi-Long
    Yang, James C. H.
    Ahn, Myung-Ju
    Ma, Rui
    Zhao, Jun
    O'Brate, Aurora
    Berghoff, Karin
    Bruns, Rolf
    Otto, Gordon
    Johne, Andreas
    Felip, Enriqueta
    Thomas, Michael
    JAMA ONCOLOGY, 2023, 9 (09) : 1260 - 1266
  • [33] Original Research Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial
    Tanaka, Kentaro
    Asahina, Hajime
    Kishimoto, Junji
    Miyata, Yoshihiro
    Uchida, Takahiro
    Watanabe, Kana
    Hamai, Kosuke
    Harada, Taishi
    Tsubata, Yukari
    Sugawara, Shunichi
    Kobayashi, Kunihiko
    Sugio, Kenji
    Oizumi, Satoshi
    Okamoto, Isamu
    EUROPEAN JOURNAL OF CANCER, 2021, 149 : 14 - 22
  • [34] Befotertinib versus icotinib as first-line treatment in patients with advanced or metastatic EGFR-mutated non-small cell lung cancer: A multicenter, randomized, open-label, controlled phase III study
    Lu, S.
    Zhou, J.
    Jian, H.
    Wu, L.
    Cheng, Y.
    Fan, Y.
    Fang, J.
    Chen, G.
    Zhang, Z.
    Lv, D.
    Jiang, L.
    Wu, R.
    Jin, X.
    Zhang, X.
    Zhang, J.
    Sun, G.
    Huang, D.
    Cui, J.
    Guo, R.
    Ding, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S1038 - S1038
  • [35] ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
    Wrangle, John M.
    Velcheti, Vamsidhar
    Patel, Manish R.
    Garrett-Mayer, Elizabeth
    Hill, Elizabeth G.
    Ravenel, James G.
    Miller, Jeffrey S.
    Farhad, Mohammad
    Anderton, Kate
    Lindsey, Kathryn
    Taffaro-Neskey, Michele
    Sherman, Carol
    Suriano, Samantha
    Swiderska-Syn, Marzena
    Sion, Amy
    Harris, Joni
    Edwards, Andie R.
    Rytlewski, Julie A.
    Sanders, Catherine M.
    Yusko, Erik C.
    Robinson, Mark D.
    Krieg, Carsten
    Redmond, William L.
    Egan, Jack O.
    Rhode, Peter R.
    Jeng, Emily K.
    Rock, Amy D.
    Wong, Hing C.
    Rubinstein, Mark P.
    LANCET ONCOLOGY, 2018, 19 (05): : 694 - 704
  • [36] Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment-naive patients with advanced EGFR mutation-positive non-small cell lung cancer: Protocol of an open-label, single-arm phase II trial
    Lee, Bora
    Ji, Wonjun
    Lee, Jae Cheol
    Song, Si Yeol
    Shin, Young Seob
    Cho, Young Hyun
    Park, Ji Eun
    Park, Hyungjun
    Choi, Chang-Min
    THORACIC CANCER, 2023, 14 (22) : 2233 - 2237
  • [37] Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
    Wu, Yi-Long
    Cheng, Ying
    Zhou, Xiangdong
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Niho, Seiji
    Tsuji, Fumito
    Linke, Rolf
    Rosell, Rafael
    Corral, Jesus
    Migliorino, Maria Rita
    Pluzanski, Adam
    Sbar, Eric I.
    Wang, Tao
    White, Jane Liang
    Nadanaciva, Sashi
    Sandin, Rickard
    Mok, Tony S.
    LANCET ONCOLOGY, 2017, 18 (11): : 1454 - 1466
  • [38] LUX-Lung 7: A Phase lib, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
    Park, K.
    Tan, E. -H.
    Zhang, L.
    Hirsh, V.
    O'Byrne, K.
    Boyer, M.
    Yang, J.
    Mok, T.
    Kim, M.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S117 - S118
  • [39] Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial
    Kato, Terufumi
    Seto, Takashi
    Nishio, Makoto
    Goto, Koichi
    Atagi, Shinji
    Hosomi, Yukio
    Yamamoto, Noboru
    Hida, Toyoaki
    Maemondo, Makoto
    Nakagawa, Kazuhiko
    Nagase, Seisuke
    Okamoto, Isamu
    Yamanaka, Takeharu
    Harada, Ryosuke
    Fukuoka, Masahiro
    Yamamoto, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial (Jun, e231962, 2023)
    不详
    JAMA ONCOLOGY, 2023, 9 (09) : 1300 - 1300
12345